

ACCESSION NUMBER: 1997024369 PCTFULL ED 20020514
 TITLE (ENGLISH): **GROWTH-HORMONE SECRETAGOGUES**
 TITLE (FRENCH): COMPOSES SECRETAGOGUES D'HORMONE DE CROISSANCE
 INVENTOR(S): CARPINO, Philip, A.; JARDINE, DaSilva, Paul, A.;
 LEFKER, Bruce, A.; RAGAN, John, A.
 PATENT ASSIGNEE(S): PFIZER INC.; CARPINO, Philip, A.; JARDINE, DaSilva,
 Paul, A.; LEFKER, Bruce, A.; RAGAN, John, A.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 9724369	A1	19970710
DESIGNATED STATES	AU BG BR BY CA CN CZ HU IL IS JP KR KZ LK LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		

APPLICATION INFO.: WO 1996-IB1353 A 19961204
 PRIORITY INFO.: US 1995-60/009,469 19951228

ABEN This invention is directed to compounds of formula (I) and the
 pharmaceutically-acceptable
 salts thereof, where the substituents are as defined in the
 Specification, which are **growth hormone**
secretagogues and which increase the level of endogenous
 growth hormone. The compounds of this
 invention are useful for the treatment and prevention of osteoporosis,
 congestive heart failure,
 frailty associated with aging, obesity; accelerating bone fracture
 repair, attenuating protein
 catabolic response after a major operation, reducing cachexia and
 protein loss due to chronic
 illness, accelerating wound healing, or accelerating the recovery of
 burn patients or patients
 having undergone major surgery; improving muscle strength, mobility,
 maintenance of skin thickness,
 metabolic homeostasis or renal homeostasis. The compounds of the
 present
 invention are also useful
 in treating osteoporosis when used in combination with: a
 bisphosphonate
 compound such as
 alendronate; estrogen, premarin, and optionally progesterone; an
 estrogen agonist or antagonist; or
 calcitonin, and pharmaceutical compositions useful therefor. Further,
 the present invention is
 directed to pharmaceutical compositions useful for increasing the
 endogenous production or release
 of growth hormone in a human or other animal which comprises an
 effective amount of a compound of
 the present invention and a **growth hormone**
secretagogue selected from GHRP-6, Hexarelin, GHRP-1,
 growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The
 invention is also directed to
 intermediates useful in the preparation of compounds of formula (I).
 ABFR L'invention concerne des composés représentés par la formule (I), ainsi
 que leurs sels
 acceptables sur le plan pharmaceutique, dans laquelle les substituants
 sont tels qu'ils sont définis
 dans la description, qui sont des secretagogues de l'hormone de

```

+-----AI-----+
AP 1998-1270      A 19980618
AU 1998-74454     A 19980605
EP 1998-921680    A 19980605
HR 1998-360       A 19980625
JP 1999-504026    A 19980605
US 1999-380887    A 19990908
US 2001-822095    A 20010330

US 2001-822109    A 20010330

US 2001-822738    A 20010330
US 2001-823051    A 20010330

WO 1998-IB873     A 19980605

```

```

+-----PI-----+
AP 9801270        A0 19980630
AU 9874454        A1 19990104
EP 1001970        A1 20000524
HR 9800360        A1 19990430
JP 2000516639     T2 20001212
US 6251902        BA 20010626
US 2002042415     AA 20020411
US 6432945        BA 20020813
US 2002002165     AA 20020103
US 6429313        BB 20020806
US 2001041703     AA 20011115
US 2002065284     AA 20020530
US 6433171        BA 20020813
WO 9858947        A1 19981230

```

L7 ANSWER 2 OF 9 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 1998058948 PCTFULL ED 20020514
 TITLE (ENGLISH): TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS
GROWTH HORMONE SECRETAGOGUE
 TITLE (FRENCH): TARTRATE DE DIPEPTIDE SUBSTITUE INTERVENANT COMME
 SECRETAGOGUE D'HORMONE DE CROISSANCE
 INVENTOR(S): CARPINO, Philip, Albert; DASILVA-JARDINE, Paul,
 Andrew;
 PATENT ASSIGNEE(S): LEFKER, Bruce, Allen; MURRY, Jerry, Anthony
 PFIZER PRODUCTS INC.; CARPINO, Philip, Albert;
 DASILVA-JARDINE, Paul, Andrew; LEFKER, Bruce, Allen;
 MURRY, Jerry, Anthony
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9858948	A1	19981230
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE	
	ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR	
	LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE	
	SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE	
	LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH	
	CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF	
	CG CI CM GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1998-IB874	A 19980605
PRIORITY INFO.:	US 1997-60/050,723	19970625

L7 ANSWER 8 OF 9 PCTFULL COPYRIGHT 2002 Univentio
 ACCESSION NUMBER: 1997024369 PCTFULL ED 20020514
 TITLE (ENGLISH): **GROWTH-HORMONE
 SECRETAGOGUES**
 TITLE (FRENCH): COMPOSES SECRETAGOGUES D'HORMONE DE CROISSANCE
 INVENTOR(S): CARPINO, Philip, A.; JARDINE, DaSilva, Paul, A.;
 LEFKER, Bruce, A.; RAGAN, John, A.
 PATENT ASSIGNEE(S): PFIZER INC.; CARPINO, Philip, A.; JARDINE, DaSilva,
 Paul, A.; LEFKER, Bruce, A.; RAGAN, John, A.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9724369	A1	19970710
DESIGNATED STATES	AU BG BR BY CA CN CZ HU IL IS JP KR KZ LK LV MX NO NZ PL RO RU SG SI SK TR UA US UZ VN AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		

APPLICATION INFO.: WO 1996-IB1353 A 19961204
 PRIORITY INFO.: US 1995-60/009,469 19951228

ABEN This invention is directed to compounds of formula (I) and the
 pharmaceutically-acceptable
 salts thereof, where the substituents are as defined in the
 Specification, which are **growth hormone**
secretagogues and which increase the level of endogenous
 growth hormone. The compounds of this
 invention are useful for the treatment and prevention of osteoporosis,
 congestive heart failure,
 frailty associated with aging, obesity; accelerating bone fracture
 repair, attenuating protein
 catabolic response after a major operation, reducing cachexia and
 protein loss due to chronic
 illness, accelerating wound healing, or accelerating the recovery of
 burn patients or patients
 having undergone major surgery; improving muscle strength, mobility,
 maintenance of skin thickness,
 metabolic homeostasis or renal homeostasis. The compounds of the
 present
 invention are also useful
 in treating osteoporosis when used in combination with: a
 bisphosphonate
 compound such as
 alendronate; estrogen, premarin, and optionally progesterone; an
 estrogen agonist or antagonist; or
 calcitonin, and pharmaceutical compositions useful therefor. Further,
 the present invention is
 directed to pharmaceutical compositions useful for increasing the
 endogenous production or release
 of growth hormone in a human or other animal which comprises an
 effective amount of a compound of
 the present invention and a **growth hormone**
secretagogue selected from GHRP-6, Hexarelin, GHRP-1,
 growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The
 invention is also directed to
 intermediates useful in the preparation of compounds of formula (I).
 ABFR L'invention concerne des composés représentés par la formule (I), ainsi
 que leurs sels
 acceptables

croissance et qui augmentent le niveau de l'hormone de croissance endogene. Ces composes sont utiles pour traiter et prevenir l'osteoporose, l'insuffisance cardiaque congestive, la fragilite associee au vieillissement, l'obesite, pour accelerer la reparation des fractures osseuses,

attenuer

la reaction catabolique proteique apres une operation lourde, limiter la cachexie et la perte proteique dues a une maladie chronique, accelerer la cicatrisation des lesions ou la coalescence de patients brules ou de patients ayant subi une intervention de chirurgie lourde, ameliorer la resistance musculaire, la mobilite, le maintien de l'epaisseur de la peau, l'homeostasie metabolique ou l'homeostasie renale. Ces composes sont egalement utiles pour traiter l'osteoporose quand on les utilise en combinaison avec un compose bisphosphate, tel qu'alendronate, des oestrogenes, premarine et, eventuellement, progesterone, un agoniste ou un antagoniste d'oestrogene, ou calcitonine, ainsi qu'avec des compositions pharmaceutiques utiles a cet effet. L'invention concerne, de plus, des compositions pharmaceutiques utiles pour augmenter la production endogene ou la liberation d'hormone de croissance chez l'homme ou chez l'animal, et comprenant une dose efficace d'un compose de l'invention et un secretagogue d'hormone de croissance selectionne

parmi

GHRP-6, Hexareline, GHRP-1, le facteur de liberation de l'hormone de croissance (GRF), IGF-1, IGF-2 ou B-HT920. L'invention concerne egalement des intermediaires utiles pour preparer les composes representes par la formule (I).

+-----AI-----+	
AT 1996-905322	EP 19960202
AU 1996-49119	A 19960202
DE 1996-69620877	A 19960202
EP 1996-905322	A 19960202
JP 1996-524328	A 19960202
US 1997-783523	A 19970114
WO 1996-US1382	A 19960202

+-----PI-----+	
AT 216590	E 20020515
AU 695129	B2 19980806
AU 9649119	A1 19960827
DE 69620877	C0 20020529
EP 820299	A1 19980128
EP 820299	B1 20020424
JP 2000510813	T2 20000822
US 5744132	A 19980428
WO 9624369	A1 19960815